image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.8114
-3.62 %
$ 77.5 M
Market Cap
-0.17
P/E
1. INTRINSIC VALUE

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis.[ Read More ]

The intrinsic value of one ASRT stock under the base case scenario is HIDDEN Compared to the current market price of 0.811 USD, Assertio Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ASRT

image
FINANCIALS
152 M REVENUE
-2.67%
-244 M OPERATING INCOME
-421.24%
-332 M NET INCOME
-302.80%
49.6 M OPERATING CASH FLOW
-36.89%
3.1 M INVESTING CASH FLOW
107.26%
-44.2 M FINANCING CASH FLOW
-467.12%
29.2 M REVENUE
-6.17%
-3.05 M OPERATING INCOME
15.73%
-2.92 M NET INCOME
20.50%
-35 K OPERATING CASH FLOW
-0.47%
-6.71 M INVESTING CASH FLOW
84.51%
-10 K FINANCING CASH FLOW
86.67%
Balance Sheet Decomposition Assertio Holdings, Inc.
image
Current Assets 171 M
Cash & Short-Term Investments 73.4 M
Receivables 47.7 M
Other Current Assets 50 M
Non-Current Assets 115 M
Long-Term Investments 0
PP&E 2.04 M
Other Non-Current Assets 113 M
Current Liabilities 93.4 M
Accounts Payable 13.4 M
Short-Term Debt 928 K
Other Current Liabilities 79.1 M
Non-Current Liabilities 55 M
Long-Term Debt 40 M
Other Non-Current Liabilities 15 M
EFFICIENCY
Earnings Waterfall Assertio Holdings, Inc.
image
Revenue 152 M
Cost Of Revenue 27 M
Gross Profit 125 M
Operating Expenses 369 M
Operating Income -244 M
Other Expenses 88.4 M
Net Income -332 M
RATIOS
82.23% GROSS MARGIN
82.23%
-160.15% OPERATING MARGIN
-160.15%
-218.28% NET MARGIN
-218.28%
-240.53% ROE
-240.53%
-115.89% ROA
-115.89%
-180.27% ROIC
-180.27%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Assertio Holdings, Inc.
image
Net Income -332 M
Depreciation & Amortization 28.2 M
Capital Expenditures -628 K
Stock-Based Compensation 9.16 M
Change in Working Capital 140 K
Others 254 M
Free Cash Flow 49 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Assertio Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for ASRT of $2.88 , with forecasts ranging from a low of $2.75 to a high of $3 .
ASRT Lowest Price Target Wall Street Target
2.75 USD 238.92%
ASRT Average Price Target Wall Street Target
2.88 USD 254.33%
ASRT Highest Price Target Wall Street Target
3 USD 269.73%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Assertio Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
11.5 K USD 1
9-12 MONTHS
0 USD 0
Bought
9.95 K USD 1
0-3 MONTHS
35.4 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 days ago
Nov 14, 2024
Bought 9.95 K USD
O'Grady Brendan P.
CEO
+ 11706.462
0.85 USD
5 months ago
Jun 11, 2024
Bought 11.1 K USD
Vacirca Jeff L
Director
+ 10000
1.11 USD
5 months ago
Jun 05, 2024
Bought 24.2 K USD
Mason Heather L
Interim Executive Officer
+ 25000
0.97 USD
8 months ago
Mar 14, 2024
Sell 11.5 K USD
Tyree James L
Director
- 10251
1.1182 USD
1 year ago
Sep 11, 2023
Sell 137 K USD
Schlessinger Sam
SVP, General Counsel
- 45236
3.0383 USD
1 year ago
Sep 11, 2023
Sell 196 K USD
Patel Ajay
SVP and CAO
- 64313
3.0444 USD
1 year ago
Sep 11, 2023
Sell 323 K USD
Schwichtenberg Paul
SVP and CFO
- 104980
3.0729 USD
1 year ago
Sep 11, 2023
Sell 387 K USD
Peisert Daniel A.
President & CEO
- 127281
3.0403 USD
1 year ago
Sep 12, 2023
Sell 92.4 K USD
Peisert Daniel A.
President & CEO
- 31121
2.9701 USD
1 year ago
Aug 14, 2023
Sell 69 K USD
MCKEE WILLIAM
Director
- 22000
3.1384 USD
1 year ago
May 19, 2023
Sell 652 K USD
Mason Heather L
Director
- 89286
7.3025 USD
1 year ago
May 05, 2023
Sell 259 K USD
Tyree James L
Director
- 43143
5.9979 USD
2 years ago
May 12, 2022
Sell 105 K USD
Tyree James L
director:
- 44643
2.3558 USD
2 years ago
May 12, 2022
Sell 52.5 K USD
MCKEE WILLIAM
director:
- 22322
2.3514 USD
2 years ago
Apr 11, 2022
Sell 92.4 K USD
Peisert Daniel A.
President and CEO
- 26391
3.5 USD
2 years ago
Apr 05, 2022
Sell 121 K USD
Peisert Daniel A.
President and CEO
- 34518
3.5 USD
3 years ago
May 20, 2021
Bought 14.8 K USD
Schwichtenberg Paul
SVP and CFO
+ 9750
1.514 USD
3 years ago
May 20, 2021
Bought 24.5 K USD
Peisert Daniel A.
President and CEO
+ 15909
1.54 USD
3 years ago
May 20, 2021
Bought 12.5 K USD
Patel Ajay
SVP and CAO
+ 8169.934
1.53 USD
3 years ago
Dec 23, 2020
Sell 2.54 M USD
CR Group L.P.
10 percent owner
- 6784334
0.3745 USD
3 years ago
Dec 24, 2020
Sell 730 K USD
CR Group L.P.
10 percent owner
- 1982851
0.3682 USD
3 years ago
Dec 18, 2020
Sell 189 K USD
CR Group L.P.
10 percent owner
- 500000
0.3776 USD
3 years ago
Dec 21, 2020
Sell 180 K USD
CR Group L.P.
10 percent owner
- 500000
0.3602 USD
3 years ago
Dec 22, 2020
Sell 509 K USD
CR Group L.P.
10 percent owner
- 1500000
0.339 USD
4 years ago
May 08, 2020
Sell 12.5 K USD
DAWES KAREN A
Director
- 15834
0.7914 USD
5 years ago
Nov 11, 2019
Bought 9.91 K USD
STAPLE PETER D
Director
+ 13900
0.713 USD
5 years ago
Nov 12, 2019
Bought 18.2 K USD
HIGGINS ARTHUR J
Director, President and CEO
+ 25000
0.73 USD
5 years ago
Aug 19, 2019
Bought 40.2 K USD
HIGGINS ARTHUR J
Director, President and CEO
+ 25000
1.6097 USD
5 years ago
Aug 13, 2019
Bought 6.23 K USD
Bukofzer Stan
SVP, Chf Scitfc & Tech Officer
+ 4000
1.557 USD
5 years ago
Aug 12, 2019
Bought 76.9 K USD
HIGGINS ARTHUR J
Director, President and CEO
+ 50000
1.538 USD
5 years ago
Jun 13, 2019
Sell 39.8 K USD
DAWES KAREN A
Director
- 12500
3.1835 USD
5 years ago
Mar 14, 2019
Bought 41.7 K USD
HIGGINS ARTHUR J
Director, President and CEO
+ 10000
4.17 USD
5 years ago
Mar 14, 2019
Bought 20.7 K USD
Bukofzer Stan
SVP, Chf Scitfc & Tech Officer
+ 5000
4.1315 USD
5 years ago
Dec 03, 2018
Sell 40.7 K USD
DAWES KAREN A
Director
- 8421
4.8361 USD
7. News
Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that recently inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today called upon the Senate Committee on Health, Education, Labor & Pensions (the “Committee”) to investigate the evident product-related fraud at. businesswire.com - 1 day ago
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT ) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - CEO Ajay Patel - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners Raghuram Selvaraju - H.C. Wainwright Operator Thank you for standing by. seekingalpha.com - 5 days ago
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates Assertio (ASRT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.01 per share a year ago. zacks.com - 5 days ago
Assertio Reports Third Quarter 2024 Financial Results Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million  Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, 2024. globenewswire.com - 5 days ago
Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today responded to the Company's attempt to deny, in its November 11, 2024, press release, the evident product-related fraud at Spectrum Pharmaceuticals, In. businesswire.com - 5 days ago
Assertio Provides Response to Letter from Short-seller Claims about Rolvedon and Assertio's Accounting Practices are False and Baseless Short-seller's Press Release is Another Improper Attempt to Enrich Himself at Assertio's Expense Company Considering Taking Legal and Regulatory Action LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today issued the following letter from Chief Executive Officer Brendan O'Grady in response to public comments made November 8, 2024 by a short-seller: To the members of the investment community, As many of you have been aware, Mr. globenewswire.com - 5 days ago
Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has now inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today released an open letter to Assertio stockholders. “Today, BHG has sadly been forced to issue a letter to Assertio stockholders, in light of the bo. businesswire.com - 1 week ago
Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Brendan O'Grady, Chief Executive Officer, will participate in a fireside chat discussion as part of the Maxim Group 2024 Healthcare Virtual Summit. The fireside chat with Mr. O'Grady, hosted by Maxim Group research analyst Naz Rahman, will occur Tuesday, October 15, 2024 at 1:00 pm Eastern Time. globenewswire.com - 1 month ago
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) LAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective October 1, 2024, the Compensation Committee of the Company's Board of Directors granted two newly-hired employees a total of 16,325 restricted stock units (“RSUs”) and 24,670 stock options (“options”). globenewswire.com - 1 month ago
Assertio Holdings: Management Change Could Improve Comeback Chances After losing exclusivity with its prior flagship drug, pharma firm Assertio Holdings (ASRT) is angling for a comeback with a new flagship drug product. However, Assertio's latest fiscal results were mixed at best, suggesting challenges ahead with its turnaround efforts. Still, with a new CEO at the helm, there may now be greater potential for ASRT to not only experience improved fiscal performance, but experience a market re-rating as well. seekingalpha.com - 2 months ago
Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024 LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief Financial Officer, will host investor meetings at two investor conferences taking place in New York City during September 10-12, 2024. globenewswire.com - 2 months ago
Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript Assertio Holdings, Inc. (NASDAQ:ASRT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - Chief Executive Officer Ajay Patel - Senior Vice President and Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Raghuram Selvaraju - H.C. Wainwright Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners James Sidoti - Sidoti and Company Operator Thank you for standing by. seekingalpha.com - 3 months ago
8. Profile Summary

Assertio Holdings, Inc. ASRT

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 77.5 M
Dividend Yield 0.00%
Description Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Contact 100 South Saunders Road, Lake Forest, IL, 60045 https://www.assertiotx.com
IPO Date Dec. 3, 1997
Employees 53
Officers Mr. Bill Iskos Senior Vice President of Operations Mr. Paul Schwichtenberg Senior Vice President & Chief Commercial Officer Ms. Molly Dir Senior Vice President of HR & Administration Mr. Ajay Patel Senior Vice President & Chief Financial Officer Mr. Sam Schlessinger Senior Vice President & General Counsel Mr. Brendan P. O'Grady Chief Executive Officer & Director Dr. Howard J. Franklin M.B.A., M.D. Senior Vice President of Medical